Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination

The ability to induce humoral and cellular immunity via antigen delivery through the unbroken skin (epicutaneous immunization, EPI) has immediate relevance for vaccine development. However, it is unclear which adjuvants induce protective memory CD8 T-cell responses by this route, and the molecular and cellular requirements for priming through intact skin are not defined. We report that cholera toxin (CT) is superior to other adjuvants in its ability to prime memory CD8 T cells that control bacterial and viral challenges. Epicutaneous immunization with CT does not require engagement of classic toll-like receptor (TLR) and inflammasome pathways and, surprisingly, is independent of skin langerin-expressing cells (including Langerhans cells). However, CT adjuvanticity required type-I IFN sensitivity, participation of a Batf3-dependent dendritic cell (DC) population and engagement of CT with suitable gangliosides. Chemoenzymatic generation of CT–antigen fusion proteins led to efficient priming of the CD8 T-cell responses, paving the way for development of this immunization strategy as a therapeutic option.

[1]  Carla P. Guimarães,et al.  Identification of host cell factors required for intoxication through use of modified cholera toxin , 2011, The Journal of cell biology.

[2]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[3]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[4]  R. Germain,et al.  Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. , 2011, The Journal of clinical investigation.

[5]  H. Schild,et al.  UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin. , 2011, The Journal of investigative dermatology.

[6]  M. Hermann,et al.  Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin. , 2010, Immunobiology.

[7]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[8]  K. Murphy,et al.  Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells , 2010, The Journal of experimental medicine.

[9]  N. Romani,et al.  Langerhans cells and more: langerin‐expressing dendritic cell subsets in the skin , 2010, Immunological reviews.

[10]  A. Brooks,et al.  Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells , 2009, Nature Immunology.

[11]  H. Ploegh,et al.  Site‐Specific Protein Labeling via Sortase‐Mediated Transpeptidation , 2009, Current protocols in protein science.

[12]  S. Jameson,et al.  The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion , 2009, The Journal of experimental medicine.

[13]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[14]  G. Glenn,et al.  Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. , 2008, Vaccine.

[15]  S. Jameson,et al.  Langerin Expressing Cells Promote Skin Immune Responses under Defined Conditions1 , 2008, The Journal of Immunology.

[16]  Kylie M. Price,et al.  Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells1 , 2008, The Journal of Immunology.

[17]  K. Hogquist,et al.  Identification of a novel population of Langerin+ dendritic cells , 2007, The Journal of experimental medicine.

[18]  Gideon Kersten,et al.  Needle-free vaccine delivery , 2007, Expert opinion on drug delivery.

[19]  B. Beutler,et al.  TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.

[20]  Li-Fang Wang,et al.  Cross‐priming with an epicutaneously introduced soluble protein antigen generates Tc1 cells , 2006, European journal of immunology.

[21]  G. Glenn,et al.  GM1 Binding-Deficient Exotoxin Is a Potent Noninflammatory Broad Spectrum Intradermal Immunoadjuvant , 2006, The Journal of Immunology.

[22]  B. Beutler,et al.  Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway. , 2006, Immunity.

[23]  Kylie M. Price,et al.  Langerhans cells cross-present antigen derived from skin , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  James D. Campbell,et al.  Needle-free vaccine delivery. , 2006, Advanced drug delivery reviews.

[25]  S. Jameson,et al.  The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells , 2006, Nature Immunology.

[26]  M. Jobling,et al.  The Cholera Toxin A13 Subdomain Is Essential for Interaction with ADP-Ribosylation Factor 6 and Full Toxic Activity but Is Not Required for Translocation from the Endoplasmic Reticulum to the Cytosol , 2006, Infection and Immunity.

[27]  E. Turlizzi,et al.  Bcl-2 down modulation in WEHI-3B/CTRES cells resistant to Cholera Toxin (CT)-induced apoptosis , 2006, Cell Research.

[28]  E. Celis,et al.  Transcutaneous Immunization with Cytotoxic T-Cell Peptide Epitopes Provides Effective Antitumor Immunity in Mice , 2005, Journal of immunotherapy.

[29]  P. Perrin,et al.  Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. , 2005, Immunity.

[30]  H. Schild,et al.  Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod1 , 2005, The Journal of Immunology.

[31]  S. Akira,et al.  ASC is essential for LPS‐induced activation of procaspase‐1 independently of TLR‐associated signal adaptor molecules , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[32]  E. Pamer.  Immune responses to Listeria monocytogenes , 2004, Nature Reviews Immunology.

[33]  S. Muller,et al.  Modulation of immune responses with transcutaneously deliverable adjuvants. , 2004, Vaccine.

[34]  S. Semple,et al.  Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL. , 2004, The Journal of investigative dermatology.

[35]  J. Berzofsky,et al.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. , 2004, The Journal of clinical investigation.

[36]  D. Taub,et al.  Quantitative differences in lipid raft components between murine CD4+ and CD8+ T cells , 2004, BMC Immunology.

[37]  J. Mcghee,et al.  Cholera toxin activates dendritic cells through dependence on GM1‐ganglioside which is mediated by NF‐κB translocation , 2003, European journal of immunology.

[38]  S. Akira,et al.  Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.

[39]  R. Tan,et al.  Optimization of epicutaneous immunization for the induction of CTL. , 2003, Vaccine.

[40]  D. Schmitt,et al.  Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against respiratory syncytial virus (RSV). , 2003, Vaccine.

[41]  M. Wolf,et al.  Safety and Immunogenicity of a Prototype Enterotoxigenic Escherichia coli Vaccine Administered Transcutaneously , 2002, Infection and Immunity.

[42]  C. Alving,et al.  Transcutaneous Immunization Using Colonization Factor and Heat-Labile Enterotoxin Induces Correlates of Protective Immunity for Enterotoxigenic Escherichia coli , 2002, Infection and Immunity.

[43]  M. Jobling,et al.  Biological and Biochemical Characterization of Variant A Subunits of Cholera Toxin Constructed by Site-Directed Mutagenesis , 2001, Journal of bacteriology.

[44]  P. Wollan,et al.  Making vaccines more acceptable--methods to prevent and minimize pain and other common adverse events associated with vaccines. , 2001, Vaccine.

[45]  C. Alving,et al.  Transcutaneous immunization: A human vaccine delivery strategy using a patch , 2000, Nature Medicine.

[46]  K. Mohlke,et al.  Mvwf, a Dominant Modifier of Murine von Willebrand Factor, Results from Altered Lineage-Specific Expression of a Glycosyltransferase , 1999, Cell.

[47]  C. Alving,et al.  Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. , 1998, Journal of immunology.

[48]  G. Matyas,et al.  Skin immunization made possible by cholera toxin , 1998, Nature.

[49]  J. Viallet,et al.  Cholera toxin triggers apoptosis in human lung cancer cell lines. , 1997, Cancer research.

[50]  K. Takamiya,et al.  Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M Aguet,et al.  Functional role of type I and type II interferons in antiviral defense. , 1994, Science.